Dr. Yang brings extensive experience in leading early-stage clinical trials and late stage global registrational trials

杨博士在领导早期临床试验和后期全球注册试验方面拥有丰富的经验

LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

伦敦和剑桥，马萨诸塞州，2023年10月10日/PRNewswire/-Pheon Therapeutics（Pheon），一家领先的抗体-药物偶联物（ADC）公司，为广泛的难治性癌症开发下一代ADC，很高兴宣布任命首席医疗官Arvin Yang博士。

Dr. Yang joins Pheon with over a decade of experience in leading therapeutic oncology products through early-stage clinical development, and late-stage global registration trials at both Bristol Myers Squibb and Mersana Therapeutics.

Yang博士通过早期临床开发和Bristol-Myers Squibb和Mersana Therapeutics的后期全球注册试验，加入Pheon，拥有十多年的领先治疗肿瘤产品经验。

Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: 'As a seasoned Chief Medical Officer, Dr. Yang's extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company. His deep knowledge of oncology clinical development will be invaluable as we advance our first-in-class ADCs for the treatment of solid tumors.'.

Pheon Therapeutics首席执行官Cyrus Mozayeni说：“作为一名经验丰富的首席医疗官，杨博士广泛的行业和领导经验使他能够完美地将Pheon作为临床阶段公司进入我们成长的下一阶段。随着我们推进用于治疗实体瘤的一流ADC，他对肿瘤学临床开发的深入了解将是无价的。

Dr. Arvin Yang, newly appointed Chief Medical Officer of Pheon Therapeutics, commented: 'Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumors. We are now preparing to transition into clinical development and are working diligently to improve outcomes for patients facing hard-to-treat cancers.'.

新任命的Pheon Therapeutics首席医疗官Arvin Yang博士评论说：“Pheon致力于推进针对实体瘤的国有专有ADC，因此定位良好。我们现在正在准备过渡到临床开发阶段，并正在努力改善面临难以治疗癌症的患者的预后。

At Mersana Therapeutics, Dr. Yang oversaw the clinical development of multiple novel assets in both early and late-stage global development. Prior to his work at Mersana, Dr. Yang spent over a decade at Bristol Myers Squibb, in a variety of leadership roles, making contributions that spanned all stages of the development process, from discovery through late-stage clinical trials and approvals.

在Mersana Therapeutics，Yang博士负责全球早期和晚期发展中多种新型资产的临床开发。在Mersana工作之前，Yang博士在Bristol-Myers Squibb工作了十多年，担任各种领导角色，为开发过程的各个阶段做出贡献，从发现到后期临床试验和批准。

His work included generating clinical development plans and driving the approvals of nivolumab, ipilimumab, fedratinib, and luspatercept..

他的工作包括制定临床开发计划并推动nivolumab，ipilimumab，fedratinib和luspatercept的批准。。

Dr. Yang earned his MD and PhD from Rutgers Robert Wood Johnson Medical School, training in internal medicine at Beth Israel Deaconess, Harvard Medical School, and in oncology at Memorial Sloan-Kettering Cancer Center. He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology..

杨博士在罗格斯罗伯特伍德约翰逊医学院获得医学博士和博士学位，在哈佛医学院贝斯以色列女执事和纪念斯隆凯特琳癌症中心接受内科医学培训。他在医学学术期刊上广泛发表，被公认为血液学和肿瘤学领域的领先权威。。

About Pheon Therapeutics

关于Pheon疗法

Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types..

Pheon Therapeutics是抗体-药物偶联物（ADC）专家，为新靶点和/或新型有效载荷开发单一疗法管道。ADC提供了治疗对其他治疗没有反应的实体瘤和液体癌的潜力。Pheon的牵头项目是一流的ADC，针对在各种难以治疗的癌症类型中在实体瘤中高度表达的新靶点。。

Pheon is backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies (RCT). Pheon has a world class, proven leadership team that brings together the best of ADC engineering, clinical and managerial expertise and track record. For further information, please visit www.pheontx.com.

Pheon得到了专家，专业医疗保健投资者Atlas Venture，Brandon Capital，Forbion和Research Corporation Technologies（RCT）的支持。Pheon拥有一支世界一流的，经过验证的领导团队，汇集了ADC工程，临床和管理专业知识以及跟踪记录。欲了解更多信息，请访问www.pheontx.com。

SOURCE Pheon Therapeutics

来源Pheon疗法